Usted buscó: progression (Checo - Inglés)

progression features:
features

assotiation with tumour progression.
assotiation with tumour progression.

is this just further progression of le?
is this just further progression of le?

morbidity, progression, and treatment were analyzed.
morbidity, progression, and treatment were analyzed.

the progression of events is proposed to be:
the effect of co2:

exists, the current literature lacks data on progression
exists, the current literature lacks data on progression

(progression or regression) had been evaluated by physical
(progression or regression) had been evaluated by physical

the healing progression of the wounds was evaluated weekly.
the healing progression of the wounds was evaluated weekly.

the role of androgen receptor mutations in prostate cancer progression.
the role of androgen receptor mutations in prostate cancer progression.

a natural history model of stage progression applied to breast cancer.
a natural history model of stage progression applied to breast cancer.

the majority of patients (57.9 percent) had progression of their disease.
the majority of patients (57.9 percent) had progression of their disease.

it is likely to be most helpful in patients that have lymphatic dysfunction from progression to lipo-lymphedema.
it is likely to be most helpful in patients that have lymphatic dysfunction from progression to lipo-lymphedema.

primárním cílovým parametrem účinnosti v obou studiích byl čas do progrese (time to progression, ttp).
the primary efficacy endpoint in both studies was time to progression (ttp).

primární hodnocenou proměnnou účinnosti bylo přežití bez známek progrese (pfs - progression free survival).
the primary efficacy endpoint was progression free survival (pfs).

büchler t, et al. objective response and time to progression on sequential treatment with sunitinib and sorafenib in metastatic renal cell carcinoma.
büchler t, et al. objective response and time to progression on sequential treatment with sunitinib and sorafenib in metastatic renal cell carcinoma.

doba do progrese (time to progression - ttp) [medián, týdny (95% ci] **
time to progression (ttp) [median, weeks (95% ci)]**

bader p, burkhard fc, markwalder r, et al. disease progression and survival of patients with positive lymph nodes after radical prostatectomy.
bader p, burkhard fc, markwalder r, et al. disease progression and survival of patients with positive lymph nodes after radical prostatectomy.

primárním cílovým ukazatelem (primary endpoint) studie bylo přežití bez progrese onemocnění (progression- free survival:
the primary endpoint was progression-free survival (pfs).

společné primární cílové parametry účinnosti zahrnovaly celkové přežití a přežití bez radiografické progrese (radiographic progression-free survival, rpfs).
co-primary efficacy endpoints were overall survival and radiographic progression-free survival (rpfs).

medián doby přežití bez progrese (progression free survival, pfs) činil 47, 3 týdne (95% interval spolehlivosti:
the median time of progression free survival (pfs) was 47.3 weeks (95% ci: